In the BioHarmony Drug Report Database

"Preview" Icon

Cariprazine

Vraylar, Reagila (cariprazine) is a small molecule pharmaceutical. Cariprazine was first approved as Vraylar on 2015-09-17. It is used to treat bipolar disorder, schizophrenia, and schizophrenia spectrum and other psychotic disorders in the USA. It has been approved in Europe to treat schizophrenia. It is known to target D(2) dopamine receptor and D(3) dopamine receptor. Vraylar’s patents are valid until 2029-09-17 (FDA).

 

Trade Name

 

Reagila
 

Common Name

 

cariprazine
 

ChEMBL ID

 

CHEMBL2028019
 

Indication

 

bipolar disorder, schizophrenia, schizophrenia spectrum and other psychotic disorders
 

Drug Class

 

Atypical antipsychotic

Image (chem structure or protein)

Cariprazine structure rendering